Cargando…

TRAF2 as a key candidate gene in clinical hepatitis B-associated liver fibrosis

Objectives: Approximately 240 million individuals are infected with chronic hepatitis B virus (HBV) worldwide. HBV infection can develop into liver fibrosis. The mechanism of HBV-related liver fibrosis has not been fully understood, and there are few effective treatment options. The goal of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Cichun, Zhang, Jian, Wang, Huiwen, Zhang, Wei, Liu, Jingqing, Zhou, Nianqi, Chen, Keyu, Wang, Ying, Peng, Shifang, Fu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113534/
https://www.ncbi.nlm.nih.gov/pubmed/37091870
http://dx.doi.org/10.3389/fmolb.2023.1168250
_version_ 1785027860060176384
author Wu, Cichun
Zhang, Jian
Wang, Huiwen
Zhang, Wei
Liu, Jingqing
Zhou, Nianqi
Chen, Keyu
Wang, Ying
Peng, Shifang
Fu, Lei
author_facet Wu, Cichun
Zhang, Jian
Wang, Huiwen
Zhang, Wei
Liu, Jingqing
Zhou, Nianqi
Chen, Keyu
Wang, Ying
Peng, Shifang
Fu, Lei
author_sort Wu, Cichun
collection PubMed
description Objectives: Approximately 240 million individuals are infected with chronic hepatitis B virus (HBV) worldwide. HBV infection can develop into liver fibrosis. The mechanism of HBV-related liver fibrosis has not been fully understood, and there are few effective treatment options. The goal of this study was to use transcriptomics in conjunction with experimental validation to identify new targets to treat HBV-related liver fibrosis. Methods: To identify differentially expressed genes (DEGs), five liver tissues were collected from both healthy individuals and patients with chronic hepatitis B. NovoMagic and Java GSEA were used to screen DEGs and key genes, respectively. Immunocell infiltration analysis of RNA-seq data was, and the results were confirmed by Western blotting (WB), real-time quantitative polymerase chain reaction (RT-qPCR), and immunohistochemistry. Results: We evaluated 1,105 genes with differential expression, and 462 and 643 genes showed down- and upregulation, respectively. The essential genes, such as tumor necrosis factor (TNF) receptor-associated factor-2 (TRAF2), were screened out of DEGs. TRAF2 expression was abnormally high in hepatic fibrosis in patients with hepatitis B compared with healthy controls. The degree of hepatic fibrosis and serum levels of glutamate transaminase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) were positively linked with TRAF2 expression. TRAF2 may be crucial in controlling T lymphocyte-mediated liver fibrosis. Conclusion: Our findings imply that TRAF2 is essential for HBV-induced liver fibrosis progression, and it may potentially be a promising target for the treatment of hepatic fibrosis in hepatitis B.
format Online
Article
Text
id pubmed-10113534
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101135342023-04-20 TRAF2 as a key candidate gene in clinical hepatitis B-associated liver fibrosis Wu, Cichun Zhang, Jian Wang, Huiwen Zhang, Wei Liu, Jingqing Zhou, Nianqi Chen, Keyu Wang, Ying Peng, Shifang Fu, Lei Front Mol Biosci Molecular Biosciences Objectives: Approximately 240 million individuals are infected with chronic hepatitis B virus (HBV) worldwide. HBV infection can develop into liver fibrosis. The mechanism of HBV-related liver fibrosis has not been fully understood, and there are few effective treatment options. The goal of this study was to use transcriptomics in conjunction with experimental validation to identify new targets to treat HBV-related liver fibrosis. Methods: To identify differentially expressed genes (DEGs), five liver tissues were collected from both healthy individuals and patients with chronic hepatitis B. NovoMagic and Java GSEA were used to screen DEGs and key genes, respectively. Immunocell infiltration analysis of RNA-seq data was, and the results were confirmed by Western blotting (WB), real-time quantitative polymerase chain reaction (RT-qPCR), and immunohistochemistry. Results: We evaluated 1,105 genes with differential expression, and 462 and 643 genes showed down- and upregulation, respectively. The essential genes, such as tumor necrosis factor (TNF) receptor-associated factor-2 (TRAF2), were screened out of DEGs. TRAF2 expression was abnormally high in hepatic fibrosis in patients with hepatitis B compared with healthy controls. The degree of hepatic fibrosis and serum levels of glutamate transaminase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) were positively linked with TRAF2 expression. TRAF2 may be crucial in controlling T lymphocyte-mediated liver fibrosis. Conclusion: Our findings imply that TRAF2 is essential for HBV-induced liver fibrosis progression, and it may potentially be a promising target for the treatment of hepatic fibrosis in hepatitis B. Frontiers Media S.A. 2023-04-05 /pmc/articles/PMC10113534/ /pubmed/37091870 http://dx.doi.org/10.3389/fmolb.2023.1168250 Text en Copyright © 2023 Wu, Zhang, Wang, Zhang, Liu, Zhou, Chen, Wang, Peng and Fu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Wu, Cichun
Zhang, Jian
Wang, Huiwen
Zhang, Wei
Liu, Jingqing
Zhou, Nianqi
Chen, Keyu
Wang, Ying
Peng, Shifang
Fu, Lei
TRAF2 as a key candidate gene in clinical hepatitis B-associated liver fibrosis
title TRAF2 as a key candidate gene in clinical hepatitis B-associated liver fibrosis
title_full TRAF2 as a key candidate gene in clinical hepatitis B-associated liver fibrosis
title_fullStr TRAF2 as a key candidate gene in clinical hepatitis B-associated liver fibrosis
title_full_unstemmed TRAF2 as a key candidate gene in clinical hepatitis B-associated liver fibrosis
title_short TRAF2 as a key candidate gene in clinical hepatitis B-associated liver fibrosis
title_sort traf2 as a key candidate gene in clinical hepatitis b-associated liver fibrosis
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113534/
https://www.ncbi.nlm.nih.gov/pubmed/37091870
http://dx.doi.org/10.3389/fmolb.2023.1168250
work_keys_str_mv AT wucichun traf2asakeycandidategeneinclinicalhepatitisbassociatedliverfibrosis
AT zhangjian traf2asakeycandidategeneinclinicalhepatitisbassociatedliverfibrosis
AT wanghuiwen traf2asakeycandidategeneinclinicalhepatitisbassociatedliverfibrosis
AT zhangwei traf2asakeycandidategeneinclinicalhepatitisbassociatedliverfibrosis
AT liujingqing traf2asakeycandidategeneinclinicalhepatitisbassociatedliverfibrosis
AT zhounianqi traf2asakeycandidategeneinclinicalhepatitisbassociatedliverfibrosis
AT chenkeyu traf2asakeycandidategeneinclinicalhepatitisbassociatedliverfibrosis
AT wangying traf2asakeycandidategeneinclinicalhepatitisbassociatedliverfibrosis
AT pengshifang traf2asakeycandidategeneinclinicalhepatitisbassociatedliverfibrosis
AT fulei traf2asakeycandidategeneinclinicalhepatitisbassociatedliverfibrosis